Clearance of BK Virus Nephropathy by Combination Antiviral Therapy with Intravenous Immunoglobulin

Transplantation Direct

Volumn 3, Issue 4, 2017, Pages E142-

  Kable, Kathy ^a   Davies, Carmen D ^a   O'connell, Philip J ^a   Chapman, Jeremy R ^a   Nankivell, Brian John ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85036563079     PISSN: None     EISSN: 23738731     Source Type: Journal    
DOI: 10.1097/TXD.0000000000000641     Document Type: Article

References (32)

1. Johnston O, Jaswal D, Gill JS, et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010; 89:1057–70.
2. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003;3: 611–23.
3. Hirsch H. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005; 79:1277–86.
4. Jamboti JS. BK virus nephropathy in renal transplant recipients. Nephrology (Carlton). 2016;21:647–54.
5. Nickeleit V, Singh HK, Mihatsch MJ. Polyomavirus nephropathy: morphology, pathophysiology, and clinical management. Curr Opin Nephrol Hypertens. 2003;12:599–605.
6. Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant. 2004;4:2082–92.
7. Hirsch HH, Randhawa P. BK virus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S136–46.
8. Blanckaert K, De Vriese AS. Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. Nephrol Dial Transplant. 2006;21:3364–7.
9. Drachenberg CB, Hirsch HH, Ramos E, et al. Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. Hum Pathol. 2005;36:1245–55.
10. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77:299–311.
11. Hilton R, Tong CY. Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation. J Antimicrob Chemother. 2008; 62:855–9.
12. Jordan SC, Toyoda M, Kahwaji J, et al. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant. 2011;11:196–202.
13. Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus b19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968–77.
14. Lories RJ, Maertens JA, Ceuppens JL, et al. The use of polyclonal intravenous immunoglobulins in the prevention and treatment of infectious diseases. Acta Clin Belg. 2000;55:163–9.
15. Mofenson LM, Moye J Jr, Bethel J, et al. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. JAMA. 1992;268:483–8.
16. Anyaegbu EI, Almond PS, Milligan T, et al. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant. 2012;16: E19–24.
17. Dheir H, Sahin S, Uyar M, et al. Intensive polyoma virus nephropathy treatment as a preferable approach for graft surveillance. Transplant Proc. 2011;43:867–70.
18. Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation. 2006;81:117–20.
19. Sharma AP, Moussa M, Casier S, et al. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant. 2009;13: 123–9.
20. Vu D, Shah T, Ansari J, et al. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. Transplant Proc. 2015;47:394–8.
21. Sar A, Worawichawong S, Benediktsson H, et al. Interobserver agreement for polyomavirus nephropathy grading in renal allografts using the working proposal from the 10th Banff Conference on Allograft Pathology. Hum Pathol. 2011;42:2018–24.
22. Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation. 2006;81: 704–10.
23. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.
24. Randhawa PS, Schonder K, Shapiro R, et al. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation. 2010; 89:1462–5.
25. Farasati NA, Shapiro R, Vats A, et al. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation. 2005; 79:116–8.
26. Randhawa P, Pastrana DV, Zeng G, et al. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. Am J Transplant. 2015;15:1014–20.
27. Cohen S, Freeman T. Metabolic heterogeneity of human gamma-globulin. Biochem J. 1960;76:475–87.
28. Poulsen HL. Interstitial fluid concentrations of albumin and immunoglobulin G in normal men. Scand J Clin Lab Invest. 1974;34:119–22.
29. Bearer EL, Orci L. Endothelial fenestral diaphragms: a quick-freeze, deep-etch study. J Cell Biol. 1985;100:418–28.
30. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation. 2001;72: 419–22.
31. Mannon RB, Hoffmann SC, Kampen RL, et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant. 2005;5:2883–93.
32. Li YJ, Wu HH, Weng CH, et al. Cyclophilin A and nuclear factor of activated T cells are essential in cyclosporine-mediated suppression of polyomavirus BK replication. Am J Transplant. 2012;12:2348–62.